Adaptimmune Therapeutics PLC — Director's Dealing 2016

Jan 4, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2016-01-01

Reporting Person: Alleva Lawrence M (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares with a nominal value of GBP0.001 per share	70584	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase Ordinary Shares	$0.7400	2025-03-16	Ordinary Shares (519481)		Direct
Option to purchase Ordinary Shares	$2.8379	2025-05-11	Ordinary Shares (30745)		Direct

Footnotes

F1: Represented by 11,764 American Depositary Shares ("ADSs") held by Mr. Alleva. Mr. Alleva holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc.

F2: Exercisable as to 129,870 Ordinary Shares on March 16, 2016 and will be exercisable as to the remainder in monthly installments of 10,822 Ordinary Shares on the sixteenth of each month from April 16, 2016 through February 16, 2019, and in one installment of 10,841 Ordinary Shares on March 16, 2019.

F3: The exercise price was converted from GBP0.50 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

F4: The exercise price was converted from GBP1.82 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.